Page 4 - Scientific Library

The involvement of Prostaglandin E2 (PGE2) in cancer development has already been described (see the post "Tumour microenvironment – the dark side of PGE2). Recently, Kurtova et al. confirmed this

Many researchers are facing a dilemma: they want to set up a CRISPR genome editing project but they can't decide which cell line to use for genome editing. Even some of the most cost-effective genome editing

The term Autophagy was introduced by Christian de Duve during the Ciba Foundation Symposium on Lysosomes - which was held in London in February 1963. In 1974 he was honoured with the Nobel price in

Cell death can be caused by external factors such as infection or trauma - a process which is call necrosis. On the other hand, cell death can be mediated by intracellular programs - in this cases we talk

In a previous post, I discussed Caspases as pharmaceutical targets - how to screen for inhibitors?

Today I would like to concentrate on Caspase inhibitors/modulators, which allow for in-depth characterisation

Epothilone B is a bioactive microtubule-stabilizing small molecule. This blood-brain barrier permeable coumpound belongs to the most popular potent cytoskeletal modeling molecules for in vitro cell based

Originally identified as an active molecule against the Borrelia species, Borrelidin has since been described as a selective inhibitor of threonyl tRNA synthetase (ThrRS). More recent research has

The World Health Organization (WHO) estimated in 2008 that 1.4 billion adults worldwide were overweight and of these 500 million were obese with risks for developing type 2 diabetes, hypertension and cardio-vascular

Chronic pain of varying types including inflammatory pain, cancer pain and neuropathic pain is an increasing health problem for which there are inadequate therapeutic options.
Many new targets for analgesic

Genome editing technology enabled by CRISPR and TALEN has become mainstream. Most cell biology labs are engaged in projects to create custom cell lines with knock-outs and knock-ins, and companies such

CRISPR/Cas9 is relatively simple to implement, as the researcher fully controls the experimental design of the tools, from the sgRNA sequence to the Cas9 protein.